Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19

Biomark Med. 2020 Dec;14(17):1619-1629. doi: 10.2217/bmm-2020-0410.

Abstract

Aim: The authors studied the role of soluble ST2 (sST2) in COVID-19 and its relationship with inflammatory status and disease severity. Materials & methods: Serum levels of sST2 and interleukin (IL)-33, C-reactive protein (CRP), serum amyloid protein (SAA), IL-6 and procalcitonin (PCT), and T lymphocyte subsets from 80 subjects diagnosed with COVID-19 including 36 mild, 41 severe and three asymptomatic cases were tested. Results: Serum sST2 levels were significantly increased in COVID-19 patients, which were positively correlated with CRP, but negatively correlated with CD4+ and CD8+ T lymphocyte counts. Serum sST2 levels in nonsurviving severe cases were persistently high during disease progression. Conclusion: Serum sST2 level test is helpful for reflecting inflammatory status and illness severity of COVID-19.

Keywords: COVID-19; SARS-CoV-2; immune response; interleukin-33; soluble ST2.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • CD4-Positive T-Lymphocytes / metabolism*
  • CD8-Positive T-Lymphocytes / metabolism*
  • COVID-19 / blood*
  • Female
  • Humans
  • Interleukin-1 Receptor-Like 1 Protein / blood*
  • Male
  • Middle Aged
  • Procalcitonin / blood
  • SARS-CoV-2 / metabolism*
  • Serum Amyloid A Protein / metabolism
  • Severity of Illness Index*

Substances

  • Biomarkers
  • IL1RL1 protein, human
  • Interleukin-1 Receptor-Like 1 Protein
  • Procalcitonin
  • Serum Amyloid A Protein
  • C-Reactive Protein